China approves Epigenomics' colon cancer test

Epigenomics AG (Xetra:ECX; OTCQX:EPGNY) jumped EUR 1.03 (23%) to EUR 5.53 on Monday after China FDA approved the company's Epi proColon 2.0 non-invasive, blood-based diagnostic test for colorectal cancer.

Epigenomics said partner BioChain Institute Inc. (Newark, Calif.) conducted a study in China showing the test detected 75% of colorectal cancer cases with 97.5% specificity, and intends to launch the test within weeks. BioChain has exclusive Chinese rights to develop and commercialize the test under an expanded 2013 deal. ...